<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Tropical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/236677B5-BD5F-44C6-B1AA-3E05E7458A7B"><gtr:id>236677B5-BD5F-44C6-B1AA-3E05E7458A7B</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Checkley</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701309"><gtr:id>DEF46B10-8D25-4C9F-8ED3-566FA1E12562</gtr:id><gtr:title>Characterising the immune response to antigen 85A of non-tuberculous mycobacteria in Cape Town and Oxford.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701309</gtr:grantReference><gtr:abstractText>TB is a major health problem worldwide. TB infection rates are increasing as a result of the spread of HIV, and treatment is becoming more difficult as multi-drug resistant TB spreads. BCG works least well in tropical countries- those most affected. There is an urgent need for a more effective vaccine. 
BCG may fail in tropical countries because high levels of related ?non-tuberculous mycobacteria? (NTM) exist in the environment, to which people develop immunity. This immunity may interact with the BCG vaccine and prevent it from working effectively. 
MVA85A is a new TB vaccine being tested in Cape Town and Oxford. It is important to know the effect of NTM on this vaccine. The antigen used in the vaccine is shared in all NTM, so the impact of the vaccine may be reduced, or the opposite may occur, and pre-existing immunity to NTM may be beneficial. 
Using stored blood samples from clinical trials of MVA85A, I will determine whether people in Cape Town have greater responses to Ag85A in NTM than those in Oxford and will compare immune responses before and after vaccination. This will determine whether greater immunity to NTM results in a better or worse response to the vaccine.</gtr:abstractText><gtr:technicalSummary>BCG is significantly less effective against tuberculosis in tropical areas, probably due to the effects of background immunity to non-tuberculous mycobacteria (NTM). The first novel TB vaccine to enter clinical trials in Africa is MVA85A, based on the modified vaccinia virus Ankara and expressing antigen 85A (Ag85A). Ag85A is present in all species of mycobacteria, and is identical in M.tb and BCG, but more variable in some NTM. In the UK, MVA85A is highly immunogenic, particularly in individuals already primed by BCG. It is currently in phase 2 trials in South Africa, where preliminary results suggest it is also immunogenic, although responses vary. 

It is important to define the effects of NTM on the immunogenicity of this vaccine, as prior sensitisation by NTM may either boost vaccine responses, as appears to be happening in the UK, or inhibit them, as appears to be the case with NTM and BCG. This may depend on factors such as NTM species, dose or route of sensitisation, and differing responses to NTM may explain the variability in immune response seen in South Africa. I will investigate whether an immune response to NTM antigen 85A (Ag85A) is associated with a decreased type 1 immune response to MVA85A, comparing responses between individuals living in Oxford, an area of relatively low NTM exposure, with those living in the Western Cape, an area of very high NTM exposure. I will also determine whether South Africans have higher frequencies of T cell response to NTM Ag85A, as a result of greater NTM exposure. In doing this I will investigate the role of conventional and regulatory immune responses.</gtr:technicalSummary><gtr:fund><gtr:end>2011-10-27</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-04-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>226370</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Species of NTM which was subsequently sequenced and used in our bioinformatic pathway.</gtr:description><gtr:id>69362CA7-4D9C-417E-AED7-1928323E962E</gtr:id><gtr:impact>See other entries</gtr:impact><gtr:outcomeId>nwbXQns5dJM</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mycobacterium fortuitum mageritense deposited with ATCC</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This MySql database consists of all complete mycobacterial genome sequences and whole genome shotgun (WGS) sequences, and all proteins and predicted proteins from these sequences, which are currently in the public domain. When information on protein sequences was not available, a protein prediction algorithm was run on sequences in order to derive this information. Additionally, the mycobacterium M fortuitum was sequenced using Illumina technology, and we were provided with the unpublished and incomplete genome sequence of M parascrofulaceum.</gtr:description><gtr:id>B9A25F4F-5F2C-4CFD-92AD-27AC8D19D011</gtr:id><gtr:impact>The construction of this database has allowed us to define multiple proteins which are present in common non-tuberculous mycobacteria (NTM), but which are absent from M tuberculosis (Mtb) and other members of the Mtb family. We hope that this will allow us to define T cell responses which are specific to NTM, indicating exposure to these mycobacteria. We have gone on to select proteins which are predicted to be secreted or cell-surface associated, so are more likely to represent T cell antigens. We will next test their ability to predict exposure to NTM, first in a mouse model and then in humans who are known to have been exposed or who are naive to exposure to NTM. If successful, this will allow us to quantitate exposure to environmental mycobacteria in the context of trials of new TB vaccines, and to establish whether this exposure has an effect on the immunogenicity of these vaccines. This will also be a very useful resource for the field of bovine immunology, where exposure to NTM is thought to be of critical importance in the immunogenicity of novel TB vaccines, and is also important in the use of diagnostic reagents.</gtr:impact><gtr:outcomeId>E7E144A0BFC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Database of mycobacterial genomes and proteins</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mycobacterium fortuitum mageritense was sequenced using Illumina technology, and the sequence assembled using Velvet. The resulting whole genome shotgun sequences have been deposited at NCBI (DDBJ/EMBL/GenBank). http://www.ncbi.nlm.nih.gov/nuccore/AGSZ00000000</gtr:description><gtr:id>5522E5B4-0CB1-4EA0-B243-32C16630488E</gtr:id><gtr:impact>Used in the bioinformatic pipline described, to help define NTM-specific proteins.</gtr:impact><gtr:outcomeId>YehMNDao5ow</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Genome sequence: mycobacterium fortuitum mageritense</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/nuccore/AGSZ00000000</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Comprehensive bioinformatic pathway defined using blast search tools and a MySql database. Allowed the stringent definition of proteins present in NTM but not in the TB family. Protein and peptide blast and TblastN ensured a igh level of specificity of the process.</gtr:description><gtr:id>0E870FF7-DD64-41D0-A958-E860E3113243</gtr:id><gtr:impact>Provided to other research groups in the form of the publication cited.</gtr:impact><gtr:outcomeId>qKQ6gPRG2He</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Bioinformatic pipeline for definition of NTM-specific proteins created</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E5299DA6-C793-46B6-BB3F-1562C3509BDF</gtr:id><gtr:title>Tuberculosis vaccines: progress and challenges.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4e9adce3342cf253acf1a83df7803a2"><gtr:id>c4e9adce3342cf253acf1a83df7803a2</gtr:id><gtr:otherNames>Checkley AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>PHH1nZf3Vts</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7E069AE-FC99-4EDA-B65D-A140DF88E5CA</gtr:id><gtr:title>Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4e9adce3342cf253acf1a83df7803a2"><gtr:id>c4e9adce3342cf253acf1a83df7803a2</gtr:id><gtr:otherNames>Checkley AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>ELDb3gwY4k4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16C6B3CE-9AB4-4288-8548-817E920D39E8</gtr:id><gtr:title>Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d119e657fad9f87549b24d2df8cbde6e"><gtr:id>d119e657fad9f87549b24d2df8cbde6e</gtr:id><gtr:otherNames>Poyntz HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>54523e4c59da44.78252687</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701309</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>